 SOUTH SAN FRANCISCO, Calif., Oct. 13, 2021 GLOBE NEWSWIRE -- Vera Therapeutics, Inc. Nasdaq: VERA, a clinical-stage biotechnology company focused on developing treatments for immunological diseases that improve patients lives, announced today the upcoming presentation of clinical data for the Companys lead product candidate, atacicept, from the Phase 2a JANUS clinical trial in patients with IgA nephropathy IgAN. The data will be presented as an ePoster at the American Society of Nephrology Kidney Week 2021 Annual Meeting, being held virtually November 4-7, 2021. 